Clinical TrialsManagement highlighted concerns over potential risks associated with >85% IgG reduction, such as infection risk and stopping rules for trials.
Competitive PositionA pipeline competitor is expected to report potentially competitive data, which could pose a risk to Immunovant's market position.
Financial StabilityImmunovant has a significant annual cash burn rate, which may impact its financial stability in the absence of additional funding or revenues.